Transthyretin-related Familial Amyloid Polyneuropathy
📧 Sign up to get email alerts when something new happens for Transthyretin-related Familial Amyloid Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
A clinical trial update describing long-term follow-up plans for subjects dosed with NTLA-2001, with the study currently recruiting for ATTR…
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy [Phase 3]
A Phase 3 study of AG10 for Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) [Phase 3]
Phase 3 trial of acoramidis (AG10) for transthyretin-related familial amyloid polyneuropathy has been withdrawn.